<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="208760">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00370305</url>
  </required_header>
  <id_info>
    <org_study_id>ek. 211-02d</org_study_id>
    <nct_id>NCT00370305</nct_id>
  </id_info>
  <brief_title>11ß-HSD1 and Metabolic Syndrome</brief_title>
  <official_title>The Pathogenic Role of 11ß-Hydroxysteroid Dehydrogenase in the Metabolic Syndrome - the Effect of Rosiglitazone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the insulin sensitizing effects of
      rosiglitazone were accompanied by changes in 11ß-HSD1 expression and activity in different
      tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PPARgamma agonist rosiglitazone (R) increases insulin sensitivity, which is comparable
      to the effects of a reduction in 11ß-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity
      in animal models. We therefore aimed to investigate whether rosiglitazone-induced insulin
      sensitivity is associated with changes in 11β-HSD1 activity in different tissues in subjects
      suffering from impaired glucose tolerance.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in total, hepatic, adipose and muscular 11ß-HSD1 activity after 8 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>changes in 11ß-HSD1 expression in adipose tissue and and skeletal muscles after 8 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in insulin sensitivity after 8 weeks</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Impaired glucose tolerance

        Exclusion Criteria:

          -  Treatment with insulin

          -  Orally taken antidiabetic medication, glucocorticoids or vitamin K-antagonists

          -  Heart failure

          -  Impaired hepatic or renal function

          -  Anaemia

          -  Disturbed coagulation

          -  Any other endocrine disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Knut Mai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite, Dpt. of Endocrinology, Diabetes and Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knut Mai</last_name>
    <phone>+49-30-8445-2114</phone>
    <email>knutmai@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven Diederich, PD</last_name>
    <phone>+49-30-20915631</phone>
    <email>sven.diederich@endokrinologikum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charite, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Mai</last_name>
      <phone>+49-30-84452114</phone>
      <email>knut.mai@charite.de</email>
    </contact>
    <investigator>
      <last_name>Knut Mai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <lastchanged_date>May 11, 2007</lastchanged_date>
  <firstreceived_date>August 30, 2006</firstreceived_date>
  <keyword>11ß-hydroxysteroid dehydrogenase</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>Impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
